ArticleMedical mycology2009
The still obscure attributes of cryptococcal glucuronoxylomannan.
Article in Medical mycology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV.The Journal of infectious diseases · 2025Article
- Host-membrane lipid composition controlsFrontiers in immunology · 2025Article
- Cyclosporine Affects the Main Virulence Factors ofJournal of fungi (Basel, Switzerland) · 2023Article
- Lyophilization induces physicochemical alterations in cryptococcal exopolysaccharide.Carbohydrate polymers · 2022Article
- Review
- Mechanisms of Pulmonary Escape and Dissemination by Cryptococcus neoformans.Journal of fungi (Basel, Switzerland) · 2018Review
- Cryptococcus-Epithelial Interactions.Journal of fungi (Basel, Switzerland) · 2017Review
- The environmental yeast Cryptococcus liquefaciens produces capsular and secreted polysaccharides with similar pathogenic properties to those of C. neoformans.Scientific reports · 2017Article
- Article
- Role of the Apt1 protein in polysaccharide secretion by Cryptococcus neoformans.Eukaryotic cell · 2014Article
- Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.Future microbiology · 2014Article
- Chitin-like molecules associate with Cryptococcus neoformans glucuronoxylomannan to form a glycan complex with previously unknown properties.Eukaryotic cell · 2012Article
- In good company: association between fungal glycans generates molecular complexes with unique functions.Frontiers in microbiology · 2012Article
- Article
- Current knowledge of Trichosporon spp. and Trichosporonosis.Clinical microbiology reviews · 2011Review
- Emerging themes in cryptococcal capsule synthesis.Current opinion in structural biology · 2011Review
- Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages.The Journal of biological chemistry · 2011Article
- Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans.Eukaryotic cell · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Glucuronoxylomannan (GXM) is the major capsular polysaccharide of Cryptococcus neoformans. It is essential for fungal virulence and causes a number of deleterious effects to host cells. During the last decades, most of the experimental models designed to study the roles of GXM during cryptococcal infection were based on the stimulation of animal cells. This most commonly involved macrophages or other effector cells, with polysaccharide fractions obtained by precipitation with cationic detergents. More recently, it has been demonstrated that GXM interferes with the physiological state of other target cells, such as the epithelium. In addition, recent studies indicate that the structure of the polysaccharide and, consequently, its functions vary according with the method used for its purification. This raises questions as to what is native GXM and the significance of prior studies. In this paper, we discuss some of the aspects of GXM that are still poorly explored in the current literature, including the relevance of the polysaccharide in the interaction of cryptococci with non-phagocytic cells and the relationship between its structure and biological activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.